Jean Daniel Delbet1,2, Julien Hogan3,4, Bilal Aoun1, Iulia Stoica1,2, Rémi Salomon5, Stéphane Decramer6, Isabelle Brocheriou2,7, Georges Deschênes3,4, Tim Ulinski8,9,10. 1. Pediatric Nephrology, Armand Trousseau Hospital, APHP, 26 Avenue du Docteur Netter, Paris, 75012, France. 2. University Pierre and Marie Curie, Paris 6, Paris, France. 3. Pediatric Nephrology, Robert Debré Hospital, APHP, Paris, France. 4. University Paris Diderot, Paris 7, Paris, France. 5. Pediatric Nephrology, Necker Enfants Malades, APHP, Paris, France. 6. Pediatric Nephrology and Rheumatology, CHU Toulouse, Paris, France. 7. Pathology Department, Tenon Hospital, APHP, Paris, France. 8. Pediatric Nephrology, Armand Trousseau Hospital, APHP, 26 Avenue du Docteur Netter, Paris, 75012, France. tim.ulinski@trs.aphp.fr. 9. University Pierre and Marie Curie, Paris 6, Paris, France. tim.ulinski@trs.aphp.fr. 10. DHU i2b, Inflammation-Immunopathology-Biotherapy, Paris, France. tim.ulinski@trs.aphp.fr.
Abstract
BACKGROUND: Henoch-Schönlein purpura is the most common vasculitis in children. Its long-term prognosis depends on renal involvement. The management of Henoch-Schönlein purpura nephritis (HSPN) remains controversial. This study reports the prognosis of children with HSPN presenting with class 2 International Study of Kidney Disease in Children (ISKDC) nephritis. METHODS: All children with HSPN class 2 diagnosed between 1995 and 2015 in four pediatric nephrology centers were included, and clinical and biological data were collected from the medical files. The primary endpoint was proteinuria remission defined as a proteinuria <200 mg/L. RESULTS: Ninety-two children were included in the study with a median follow-up of 36 (6-120) months; 28% had nephrotic syndrome, 31% proteinuria >3 g/L, 52% proteinuria between 1 and 3 g/L, and 18% proteinuria <1 g/L. Forty-seven percent of patients received orally treatment with steroids alone, 37% received methylprednisolone pulses followed by steroids orally, 18% received no steroids. Although 85% reached remission during follow-up, 12% did not maintain complete remission over time so that only 75% remained in complete remission by the end of the follow-up. Univariate analysis found a higher likelihood of remission in patients with higher proteinuria at disease onset (p = 0.009). This trend was not found in the multivariate analysis after adjusting for treatments, as patients with higher proteinuria were most often treated with steroids. CONCLUSION: Our study shows that one fourth of patients with HSPN class 2 remain proteinuric and thus carry the risk of developing chronic kidney disease over the long term. This finding, together with the better outcome of patients treated with steroids, is in favor of using high-dose steroids orally or IV in these patients.
BACKGROUND: Henoch-Schönlein purpura is the most common vasculitis in children. Its long-term prognosis depends on renal involvement. The management of Henoch-Schönlein purpura nephritis (HSPN) remains controversial. This study reports the prognosis of children with HSPN presenting with class 2 International Study of Kidney Disease in Children (ISKDC) nephritis. METHODS: All children with HSPN class 2 diagnosed between 1995 and 2015 in four pediatric nephrology centers were included, and clinical and biological data were collected from the medical files. The primary endpoint was proteinuria remission defined as a proteinuria <200 mg/L. RESULTS: Ninety-two children were included in the study with a median follow-up of 36 (6-120) months; 28% had nephrotic syndrome, 31% proteinuria >3 g/L, 52% proteinuria between 1 and 3 g/L, and 18% proteinuria <1 g/L. Forty-seven percent of patients received orally treatment with steroids alone, 37% received methylprednisolone pulses followed by steroids orally, 18% received no steroids. Although 85% reached remission during follow-up, 12% did not maintain complete remission over time so that only 75% remained in complete remission by the end of the follow-up. Univariate analysis found a higher likelihood of remission in patients with higher proteinuria at disease onset (p = 0.009). This trend was not found in the multivariate analysis after adjusting for treatments, as patients with higher proteinuria were most often treated with steroids. CONCLUSION: Our study shows that one fourth of patients with HSPN class 2 remain proteinuric and thus carry the risk of developing chronic kidney disease over the long term. This finding, together with the better outcome of patients treated with steroids, is in favor of using high-dose steroids orally or IV in these patients.
Authors: Philip Kam-Tao Li; Chi Bon Leung; Kai Ming Chow; Yuk Lun Cheng; Samuel Ka-Shun Fung; Siu Ka Mak; Anthony Wing-Chung Tang; Teresa Yuk-Hwa Wong; Chun Yu Yung; Jonathan Chee-Unn Yung; Alex Wai-Yin Yu; Cheuk Chun Szeto Journal: Am J Kidney Dis Date: 2006-05 Impact factor: 8.860
Authors: O Soylemezoglu; O Ozkaya; S Ozen; A Bakkaloglu; R Dusunsel; H Peru; A Cetinyurek; N Yildiz; O Donmez; N Buyan; S Mir; N Arisoy; A Gur-Guven; H Alpay; M Ekim; N Aksu; A Soylu; F Gok; H Poyrazoglu; F Sonmez Journal: Nephron Clin Pract Date: 2009-05-13
Authors: Rachael D Wright; Julien Marro; Sarah J Northey; Rachel Corkhill; Michael W Beresford; Louise Oni Journal: Pediatr Nephrol Date: 2022-10-13 Impact factor: 3.651
Authors: Imke Hennies; Charlotte Gimpel; Jutta Gellermann; Kristina Möller; Brigitte Mayer; Katalin Dittrich; Anja K Büscher; Matthias Hansen; Wiebke Aulbert; Elke Wühl; Richard Nissel; Gessa Schalk; Lutz T Weber; Michael Pohl; Simone Wygoda; Rolf Beetz; Günter Klaus; Henry Fehrenbach; Sabine König; Hagen Staude; Ortraud Beringer; Martin Bald; Ulrike Walden; Christian von Schnakenburg; Gunhard Bertram; Michael Wallot; Karsten Häffner; Thorsten Wiech; Peter F Hoyer; Martin Pohl Journal: Pediatr Nephrol Date: 2017-10-05 Impact factor: 3.714
Authors: M Colleen Hastings; Dana V Rizk; Krzysztof Kiryluk; Raoul Nelson; Rima S Zahr; Jan Novak; Robert J Wyatt Journal: Pediatr Nephrol Date: 2021-04-05 Impact factor: 3.651